Deerfield Management Company, L.P. (Series C) Alpine Immune Sciences, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.76 Billion
Q2 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$2.15 - $4.41 $535,332 - $1.1 Million	-248,992 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$2.45 - $3.87 $386,938 - $611,204	-157,934 Reduced 38.81%	248,992 $956,000
Q3 2019 Nov 14, 2019	SELL	$3.5 - $5.0 $31,437 - $44,910	-8,982 Reduced 2.16%	406,926 $1.61 Million
Q2 2019 Aug 14, 2019	SELL	$4.08 - $7.75 $242,931 - $461,450	-59,542 Reduced 12.52%	415,908 $1.75 Million
Q4 2018 Feb 14, 2019	SELL	$3.68 - $6.07 $505,694 - $834,121	-137,417 Reduced 22.42%	475,450 $1.75 Million
Q3 2018 Nov 14, 2018	SELL	$5.68 - $8.59 $1.71 Million - $2.58 Million	-300,233 Reduced 32.88%	612,867 $3.88 Million
Q4 2017 Feb 14, 2018	SELL	$9.65 - $12.65 $193,000 - $253,000	-20,000 Reduced 2.14%	913,100 $10.2 Million
Q3 2017 Nov 13, 2017	BUY	$8.0 - $11.6 $7.46 Million - $10.8 Million	933,100	933,100 $10.8 Million

Others Institutions Holding ALPN

# of Institutions

Shares Held

56.2K

Call Options Held

Put Options Held

View Full List

About ALPINE IMMUNE SCIENCES, INC.

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

More about ALPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account